Loading…
Miller Fisher Syndrome Associated With Immunotherapy for Metastatic Melanoma
Immunotherapy is a treatment strategy that has demonstrated survival benefit for metastatic melanoma. Ipilimumab and nivolumab are examples of immunotherapy, in which monoclonal antibodies antagonize cytotoxic T-lymphocyte-associated protein 4 and programmed death-ligand 1 receptors, respectively, r...
Saved in:
| Published in: | Neurohospitalist 2018-10, Vol.8 (4), p.191-193 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c401t-ee6fd91dde3c7a7ec9e952c9513369596db007a8d05a04167277bed6517f00de3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c401t-ee6fd91dde3c7a7ec9e952c9513369596db007a8d05a04167277bed6517f00de3 |
| container_end_page | 193 |
| container_issue | 4 |
| container_start_page | 191 |
| container_title | Neurohospitalist |
| container_volume | 8 |
| creator | Baird-Gunning, Jonathan J. D. Weerasinghe, Dinushi Silsby, Matthew Gawarikar, Yash Carlino, Matteo S. Smith, Jessica L. Vucic, Steve |
| description | Immunotherapy is a treatment strategy that has demonstrated survival benefit for metastatic melanoma. Ipilimumab and nivolumab are examples of immunotherapy, in which monoclonal antibodies antagonize cytotoxic T-lymphocyte-associated protein 4 and programmed death-ligand 1 receptors, respectively, resulting in upregulation of the host immune response to cancer cells. There is increasing recognition of immune-mediated adverse events associated with immune therapies in patients with cancer. We present a case report of a patient who developed Miller Fisher syndrome associated with these therapies for metastatic melanoma along with a discussion of its management. |
| doi_str_mv | 10.1177/1941874418778957 |
| format | article |
| fullrecord | <record><control><sourceid>sage_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6146353</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_1941874418778957</sage_id><sourcerecordid>10.1177_1941874418778957</sourcerecordid><originalsourceid>FETCH-LOGICAL-c401t-ee6fd91dde3c7a7ec9e952c9513369596db007a8d05a04167277bed6517f00de3</originalsourceid><addsrcrecordid>eNp1kEFLAzEQhYMottTePcn-gdVkN9k0F6EUq4UWDyoeQ5rMtim7m5KkQv-9KdWigjnMDJP33sCH0DXBt4RwfkcEJSNOD4WPBONnqH9Y5SPOivPTTGkPDUPY4PRoVZZMXKJeiQvKOMd9NF_YpgGfTW1Yp_ay74x3LWTjEJy2KoLJ3m1cZ7O23XUuJo3a7rPa-WwBUYWootVpbFTnWnWFLmrVBBh-9QF6mz68Tp7y-fPjbDKe55piEnOAqjaCGAOl5oqDFiBYoQUjZVkJJiqzxJirkcFMYUoqXnC-BFMxwmuMk2uA7o-5292yBaOhi141cuttq_xeOmXl75_OruXKfciKJASsTAH4GKC9C8FDffISLA9w5V-4yXLz8-bJ8I0yCfKjIKgVyI3b-S4x-D_wE_nEgyk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Miller Fisher Syndrome Associated With Immunotherapy for Metastatic Melanoma</title><source>PMC (PubMed Central)</source><source>Sage Journals Online</source><creator>Baird-Gunning, Jonathan J. D. ; Weerasinghe, Dinushi ; Silsby, Matthew ; Gawarikar, Yash ; Carlino, Matteo S. ; Smith, Jessica L. ; Vucic, Steve</creator><creatorcontrib>Baird-Gunning, Jonathan J. D. ; Weerasinghe, Dinushi ; Silsby, Matthew ; Gawarikar, Yash ; Carlino, Matteo S. ; Smith, Jessica L. ; Vucic, Steve</creatorcontrib><description>Immunotherapy is a treatment strategy that has demonstrated survival benefit for metastatic melanoma. Ipilimumab and nivolumab are examples of immunotherapy, in which monoclonal antibodies antagonize cytotoxic T-lymphocyte-associated protein 4 and programmed death-ligand 1 receptors, respectively, resulting in upregulation of the host immune response to cancer cells. There is increasing recognition of immune-mediated adverse events associated with immune therapies in patients with cancer. We present a case report of a patient who developed Miller Fisher syndrome associated with these therapies for metastatic melanoma along with a discussion of its management.</description><identifier>ISSN: 1941-8744</identifier><identifier>EISSN: 1941-8752</identifier><identifier>DOI: 10.1177/1941874418778957</identifier><identifier>PMID: 30245770</identifier><language>eng</language><publisher>Los Angeles, CA: SAGE Publications</publisher><subject>Case Reports</subject><ispartof>Neurohospitalist, 2018-10, Vol.8 (4), p.191-193</ispartof><rights>The Author(s) 2018</rights><rights>The Author(s) 2018 2018 SAGE Publications</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c401t-ee6fd91dde3c7a7ec9e952c9513369596db007a8d05a04167277bed6517f00de3</citedby><cites>FETCH-LOGICAL-c401t-ee6fd91dde3c7a7ec9e952c9513369596db007a8d05a04167277bed6517f00de3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6146353/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6146353/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,724,777,781,882,27905,27906,53772,53774,79113</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30245770$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Baird-Gunning, Jonathan J. D.</creatorcontrib><creatorcontrib>Weerasinghe, Dinushi</creatorcontrib><creatorcontrib>Silsby, Matthew</creatorcontrib><creatorcontrib>Gawarikar, Yash</creatorcontrib><creatorcontrib>Carlino, Matteo S.</creatorcontrib><creatorcontrib>Smith, Jessica L.</creatorcontrib><creatorcontrib>Vucic, Steve</creatorcontrib><title>Miller Fisher Syndrome Associated With Immunotherapy for Metastatic Melanoma</title><title>Neurohospitalist</title><addtitle>Neurohospitalist</addtitle><description>Immunotherapy is a treatment strategy that has demonstrated survival benefit for metastatic melanoma. Ipilimumab and nivolumab are examples of immunotherapy, in which monoclonal antibodies antagonize cytotoxic T-lymphocyte-associated protein 4 and programmed death-ligand 1 receptors, respectively, resulting in upregulation of the host immune response to cancer cells. There is increasing recognition of immune-mediated adverse events associated with immune therapies in patients with cancer. We present a case report of a patient who developed Miller Fisher syndrome associated with these therapies for metastatic melanoma along with a discussion of its management.</description><subject>Case Reports</subject><issn>1941-8744</issn><issn>1941-8752</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp1kEFLAzEQhYMottTePcn-gdVkN9k0F6EUq4UWDyoeQ5rMtim7m5KkQv-9KdWigjnMDJP33sCH0DXBt4RwfkcEJSNOD4WPBONnqH9Y5SPOivPTTGkPDUPY4PRoVZZMXKJeiQvKOMd9NF_YpgGfTW1Yp_ay74x3LWTjEJy2KoLJ3m1cZ7O23XUuJo3a7rPa-WwBUYWootVpbFTnWnWFLmrVBBh-9QF6mz68Tp7y-fPjbDKe55piEnOAqjaCGAOl5oqDFiBYoQUjZVkJJiqzxJirkcFMYUoqXnC-BFMxwmuMk2uA7o-5292yBaOhi141cuttq_xeOmXl75_OruXKfciKJASsTAH4GKC9C8FDffISLA9w5V-4yXLz8-bJ8I0yCfKjIKgVyI3b-S4x-D_wE_nEgyk</recordid><startdate>20181001</startdate><enddate>20181001</enddate><creator>Baird-Gunning, Jonathan J. D.</creator><creator>Weerasinghe, Dinushi</creator><creator>Silsby, Matthew</creator><creator>Gawarikar, Yash</creator><creator>Carlino, Matteo S.</creator><creator>Smith, Jessica L.</creator><creator>Vucic, Steve</creator><general>SAGE Publications</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20181001</creationdate><title>Miller Fisher Syndrome Associated With Immunotherapy for Metastatic Melanoma</title><author>Baird-Gunning, Jonathan J. D. ; Weerasinghe, Dinushi ; Silsby, Matthew ; Gawarikar, Yash ; Carlino, Matteo S. ; Smith, Jessica L. ; Vucic, Steve</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c401t-ee6fd91dde3c7a7ec9e952c9513369596db007a8d05a04167277bed6517f00de3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Case Reports</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Baird-Gunning, Jonathan J. D.</creatorcontrib><creatorcontrib>Weerasinghe, Dinushi</creatorcontrib><creatorcontrib>Silsby, Matthew</creatorcontrib><creatorcontrib>Gawarikar, Yash</creatorcontrib><creatorcontrib>Carlino, Matteo S.</creatorcontrib><creatorcontrib>Smith, Jessica L.</creatorcontrib><creatorcontrib>Vucic, Steve</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Neurohospitalist</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Baird-Gunning, Jonathan J. D.</au><au>Weerasinghe, Dinushi</au><au>Silsby, Matthew</au><au>Gawarikar, Yash</au><au>Carlino, Matteo S.</au><au>Smith, Jessica L.</au><au>Vucic, Steve</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Miller Fisher Syndrome Associated With Immunotherapy for Metastatic Melanoma</atitle><jtitle>Neurohospitalist</jtitle><addtitle>Neurohospitalist</addtitle><date>2018-10-01</date><risdate>2018</risdate><volume>8</volume><issue>4</issue><spage>191</spage><epage>193</epage><pages>191-193</pages><issn>1941-8744</issn><eissn>1941-8752</eissn><abstract>Immunotherapy is a treatment strategy that has demonstrated survival benefit for metastatic melanoma. Ipilimumab and nivolumab are examples of immunotherapy, in which monoclonal antibodies antagonize cytotoxic T-lymphocyte-associated protein 4 and programmed death-ligand 1 receptors, respectively, resulting in upregulation of the host immune response to cancer cells. There is increasing recognition of immune-mediated adverse events associated with immune therapies in patients with cancer. We present a case report of a patient who developed Miller Fisher syndrome associated with these therapies for metastatic melanoma along with a discussion of its management.</abstract><cop>Los Angeles, CA</cop><pub>SAGE Publications</pub><pmid>30245770</pmid><doi>10.1177/1941874418778957</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1941-8744 |
| ispartof | Neurohospitalist, 2018-10, Vol.8 (4), p.191-193 |
| issn | 1941-8744 1941-8752 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6146353 |
| source | PMC (PubMed Central); Sage Journals Online |
| subjects | Case Reports |
| title | Miller Fisher Syndrome Associated With Immunotherapy for Metastatic Melanoma |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T02%3A50%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-sage_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Miller%20Fisher%20Syndrome%20Associated%20With%20Immunotherapy%20for%20Metastatic%20Melanoma&rft.jtitle=Neurohospitalist&rft.au=Baird-Gunning,%20Jonathan%20J.%20D.&rft.date=2018-10-01&rft.volume=8&rft.issue=4&rft.spage=191&rft.epage=193&rft.pages=191-193&rft.issn=1941-8744&rft.eissn=1941-8752&rft_id=info:doi/10.1177/1941874418778957&rft_dat=%3Csage_pubme%3E10.1177_1941874418778957%3C/sage_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c401t-ee6fd91dde3c7a7ec9e952c9513369596db007a8d05a04167277bed6517f00de3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/30245770&rft_sage_id=10.1177_1941874418778957&rfr_iscdi=true |